Literature DB >> 8571986

The reemergence of serious group A streptococcal infections and acute rheumatic fever.

M S Bronze1, J B Dale.   

Abstract

Acute rheumatic fever and life-threatening group A streptococcal infections have reemerged during the past 15 years to once again become a serious health threat in the developed countries of the world. Reports of outbreaks of acute rheumatic fever in many parts of this country and others have shattered the complacency that the health-care community had acquired related to this devastating sequela of streptococcal pharyngitis. Invasive streptococcal infections, often associated with loss of limbs of life despite optimal antibiotic therapy, have underscored the potential virulence of these organisms. A new clinical entity, streptococcal toxic shock syndrome, has emerged as a consequence of the new invasive strains of group A streptococci. In this article, the authors summarize the recent changes in the epidemiology of group A streptococcal infections and rheumatic fever and review the potential reasons for the increased virulence of these organisms. In addition, they discuss prospects for a streptococcal M protein vaccine designed to control these infections and their sequelae.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8571986     DOI: 10.1097/00000441-199601000-00008

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  20 in total

1.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

2.  Serotypes of group A streptococci isolated from healthy schoolchildren in the United Arab Emirates.

Authors:  A S Ameen; H Nsanze; K P Dawson; S Othman; N Mustafa; D R Johnson; E L Kaplan
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

3.  Protective immunogenicity of group A streptococcal M-related proteins.

Authors:  James B Dale; Shannon E Niedermeyer; Tina Agbaosi; Nicholas D Hysmith; Thomas A Penfound; Claudia M Hohn; Matthew Pullen; Michael I Bright; Daniel S Murrell; Lori E Shenep; Harry S Courtney
Journal:  Clin Vaccine Immunol       Date:  2015-01-28

4.  Superantigen-induced T cell responses in acute rheumatic fever and chronic rheumatic heart disease patients.

Authors:  A Bhatnagar; A Grover; N K Ganguly
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

5.  Generation and surface localization of intact M protein in Streptococcus pyogenes are dependent on sagA.

Authors:  I Biswas; P Germon; K McDade; J R Scott
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 6.  Streptococcal pharyngitis in children: to treat or not to treat?

Authors:  Daan Van Brusselen; Erika Vlieghe; Petra Schelstraete; Frederic De Meulder; Christine Vandeputte; Kristien Garmyn; Wim Laffut; Patrick Van de Voorde
Journal:  Eur J Pediatr       Date:  2014-08-12       Impact factor: 3.183

7.  Vaccine strategies to prevent rheumatic fever.

Authors:  E R Brandt; M F Good
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

8.  Identification of rocA, a positive regulator of covR expression in the group A streptococcus.

Authors:  Indranil Biswas; June R Scott
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

9.  Rheumatic fever in a 2-year-old child.

Authors:  Hema Nirmal; Pooja Vani; Manoj Chhabra; Nitin Ron
Journal:  Pediatr Cardiol       Date:  2007-10-19       Impact factor: 1.655

10.  Inference of antibiotic resistance and virulence among diverse group A Streptococcus strains using emm sequencing and multilocus genotyping methods.

Authors:  David Metzgar; Darcie Baynes; Christian J Hansen; Erin A McDonough; Daisy R Cabrera; Melody M Ellorin; Patrick J Blair; Kevin L Russell; Dennis J Faix
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.